The HbA1c/C-peptide ratio is associated with the no-reflow phenomenon in patients with ST-elevation myocardial infarction
Yükleniyor...
Dosyalar
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Sage Publications Inc
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Currently, the gold standard treatment for ST-elevation myocardial infarction (STEMI) is primary percutaneous coronary intervention (pPCI), but even after successful pPCI, a perfusion disorder in the epicardial coronary arteries, termed no-reflow phenomenon (NR), can develop, resulting in short- and long-term adverse events. The present study assessed the relationship between NR and HbA1c/C-peptide ratio (HCR) in 1834 consecutive patients who underwent pPCI due to STEMI. Participants were divided into two groups according to NR status and the demographic, clinical and periprocedural characteristics of the groups were compared. NR developed in 352 (19.1%) of the patients in the study. While C-peptide levels were significantly lower in the NR group, HbA1c and HCR were significantly higher (P < .001, for all). In multivariable analysis, C-peptide, HbA1c, and HCR, were determined as independent predictors for NR (P < .05, for all). In Receiver Operating Characteristic (ROC) analysis, HCR predicted the NR with 80% specificity and 77% sensitivity. In STEMI patients, combining HbA1c and C-peptide in a single fraction has a predictive value for NR independent of diabetes. This ratio may contribute to risk stratification of STEMI patients.
Açıklama
Anahtar Kelimeler
C-Peptide, HbA1c, No-Reflow, ST-Elevation Myocardial Infarction, Primary Percutaneous Coronary Intervention
Kaynak
Angiology
WoS Q Değeri
Q2
Scopus Q Değeri
Q2
Cilt
Sayı
Künye
Toprak, K., Kaplangoray, M., Memioğlu, T., İnanır, M., Omar, B., Ermiş, M. F., ... & Demirbağ, R. (2023). The HbA1c/C-peptide ratio is associated with the No-reflow phenomenon in patients with ST-elevation myocardial infarction. Angiology, 00033197231213166.